Synthesis and pharmacological properties of new 3-ethoxycarbonyl-11H-[1,2,4]triazolo[4,5-c][2,3]benzodiazepines

Farmaco

Volumn 57, Issue 9, 2002, Pages 759-763

  Chimirri, A ^a   Gitto, Rosaria ^a   Quartarone, S ^a   Orlando, V ^a   De Sarro, A ^b   De Sarro, G B ^c  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c Univ 'Magna Gracia' C   (Italy)

Author keywords

3 Ethoxycarbonyl 11H 1,2,4 triazolo 4,5 c 2,3 benzodiazepines; AMPA receptor antagonists; Anticonvulsant agents

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 6 (3 AMINOPHENYL) 8,9 DIMETHOXY 3 ETHOXYCARBONYL 11H [1,2,4]TRIAZOLO[4,5 C][2,3]BENZODIAZEPINE; 6 (4 AMINOPHENYL) 8,9 DIMETHOXY 3 ETHOXYCARBONYL 11H [1,2,4]TRIAZOLO[4,5 C][2,3]BENZODIAZEPINE; 8,9 DIMETHOXY 3 ETHOXYCARBONYL 6 (3 NITROPHENYL) 11H [1,2,4]TRIAZOLO[4,5 C][2,3]BENZODIAZEPINE; 8,9 DIMETHOXY 3 ETHOXYCARBONYL 6 (4 FLUOROPHENYL) 11H [1,2,4]TRIAZOLO[4,5 C][2,3]BENZODIAZEPINE; 8,9 DIMETHOXY 3 ETHOXYCARBONYL 6 (4 NITROPHENYL) 11H [1,2,4]TRIAZOLO[4,5 C][2,3]BENZODIAZEPINE; 8,9 DIMETHOXY 3 ETHOXYCARBONYL 6 PHENYL 11H [1,2,4]TRIAZOLO[4,5 C][2,3]BENZODIAZEPINE; AMPA RECEPTOR ANTAGONIST; BENZODIAZEPINE DERIVATIVE; CFM 2; UNCLASSIFIED DRUG; AMPA RECEPTOR; ANTICONVULSIVE AGENT; ANXIOLYTIC AGENT;

ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; AUDITORY STIMULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; MALE; MOUSE; NONHUMAN; SEIZURE; STRUCTURE ACTIVITY RELATION; ANIMAL; DRUG ANTAGONISM; DRUG SCREENING; SYNTHESIS;

ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; BENZODIAZEPINES; DRUG EVALUATION, PRECLINICAL; MICE; RECEPTORS, AMPA; SEIZURES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036753715     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(02)01272-7     Document Type: Article

References (24)

1. Doble A. Excitatory amino acid receptors and neurodegeneration. Therapie. 50:1995;319-337.
2. Muir K.W., Lees K.R. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 26:1995;503-513.
3. McEntee W.C., Crook T.H. Glutamate, its role in learning, memory, and the aging brain. Psychopharmacology. 111:1993;391-401.
4. Dingledine R., Borges K., Bowie D., Traynelis S.R. The glutamate receptor ion channels. Pharmacol. Rev. 51:1999;7-61.
5. Lees G.J. Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders. Drugs. 59:2000;33-78.
6. Lin Z., Kadaba P.K. Molecular targets for the rational design of antiepileptic drugs and related neuroprotective agents. Med. Res. Rev. 17:1997;537-572.
7. Rogawski M.A., Donevan S.D. AMPA receptors in epilepsy and as targets for antiepileptic drugs. Adv. Neurol. 79:1999;947-963.
8. Chimirri A., Gitto R., Zappalà M. AMPA receptor antagonists. Expert Opin. Ther. Pat. 9:1999;557-570.
9. Chapman A.G., Al-Zubaidy Z., Meldrum B.S. Aniracetam reverses the anticonvulsant action of NBQX and GYKI 52466 in DBA/2 Mice. Eur. J. Pharmacol. 231:1993;301-303.
10. Donevan S.D., Rogawski M.A. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/Kainate receptor responses. Neuron. 10:1993;51-59.
11. Rogawski M.A. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol. Sci. 14:1993;325-331.
12. De Sarro G., Chimirri A., De Sarro A., Gitto R., Grasso S., Giusti P., Chapman A.G. GYKI 52466 and related 2,3-benzodiazepines as anticonvulsant agents in DBA/2 Mice. Eur. J. Pharmacol. 294:1995;411-422.
13. Chimirri A., De Sarro G., De Sarro A., Gitto R., Grasso S., Quartarone S., Zappalà M., Giusti P., Libri V., Constanti A., Chapman A.G. 1-Aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones: novel AMPA receptor antagonists. J. Med. Chem. 40:1997;1258-1269. CFM-2 Tocris Catalogue 2000, www.tocris.com.
14. De Sarro G., Rizzo M., Sinopoli V.A., Gitto R., De Sarro A., Zappalà M., Chimirri A. Relationship between anticonvulsant activity and plasma level of some 2,3-benzodiazepines in genetically epilepsy prone rats. Pharmacol. Biochem. Behav. 61:1998;215-220.
15. De Sarro G., Rizzo M., Spagnolo C., Gitto R., De Sarro A., Scotto G., Zappalà M., Chimirri A. Anticonvulsant activity and plasma level of some 2,3-benzodiazepin-4-ones (CFMs) in genetically epilepsy prone rats. Pharmacol. Biochem. Behav. 63:1999;621-627.
16. Chimirri A., De Sarro G., De Sarro A., Gitto R., Quartarone S., Zappalà M., Constanti A., Libri V. 3,5-Dihydro-4H-2,3-benzodiazepine-4-thiones: a new class of AMPA receptor antagonists. J. Med. Chem. 41:1998;3409-3416.
17. Gitto R., Zappalà M., De Sarro G., Chimirri A. Design and development of 2,3-benzodiazepine (CFM) noncompetitive AMPA receptor antagonists. Farmaco. 57:2002;0000.
18. Chimirri A., Zappalà M., Gitto R., Quartarone S., Bevacqua F. Synthesis and structural features of 11H-tetrazolo[1,5-c][2,3]-benzodiazepines. Heterocycles. 51:1999;1303-1309.
19. Chimirri A., Bevacqua F., Gitto R., Quartarone S., Zappalà M., De Sarro A., Maciocco L., Biggio G., De Sarro G. Synthesis and anticonvulsant activity of new 11H-triazolo[4,5-c][2,3]benzodiazepines. Med. Chem. Res. 9:1999;203-212.
20. Zappalà M., Gitto R., Bevacqua F., Quartarone S., Chimirri A., Rizzo M., De Sarro G., De Sarro A. Synthesis and evaluation of pharmacological and pharmacokinetic properties of 11H-[1,2,4]triazolo[4,5-c][2,3]benzodiazepin-3(2H)-ones. J. Med. Chem. 43:2000;4834-4839.
21. Collins R.L. Audiogenic seizures. Purpura P., Penry J.K., Tower D., Woodbury D.M., Walter R., Experimental Models of Epilepsy. 1972;347-372 Raven Press, New York.
22. De Sarro G.B., Croucher M.J., Meldrum B.S. Anticonvulsant actions of DS 103-282: pharmacological studies in rodents and the baboon Papio papio. Neuropharmacology. 23:1984;526-530.
23. De Sarro G.B., Ongini E., Bertorelli R., Aguglia U., De Sarro A. Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of Felbamate in DBA/2 mice. Eur. J. Pharmacol. 262:1994;11-19.
24. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effects experiments. J. Pharmacol. Exp. Ther. 96:1949;99-113.